Biogen (BIIB) Receivables (2009 - 2026)
Biogen (BIIB) posted quarterly Receivables of $1.9 billion for Q2 2026, up 16.09% year-over-year from $1.6 billion in Q2 2025, and up 37.72% quarter-over-quarter from $1.4 billion in Q1 2026.
Biogen (BIIB) Receivables (2009 - 2026) Analysis & Trends
Biogen's Receivables history runs 18 years deep, the most recent figure standing at $1.9 billion for Q2 2026.
- In Q2 2026, Receivables rose 16.09% year-over-year to $1.9 billion; the TTM figure through Jun 2026 stood at $1.9 billion (up 16.09% YoY), while the FY2025 annual figure was $1.3 billion, down 4.44% from the prior year.
- Receivables for Q2 2026 stood at $1.9 billion, up from $1.4 billion in the prior quarter.
- The five-year high for Receivables was $3.2 billion in Q3 2023, with the low at $4.4 million in Q4 2025.
- The 5-year median for Receivables is $1.7 billion (2023), against an average of $1.7 billion.
- The sharpest annual moves came in 2022 and 2025: Receivables jumped 46.18% in 2022, then slumped 99.69% in 2025.
- Biogen's Receivables stood at $1.7 billion in 2022, then rose by 4.49% to $1.8 billion in 2023, then decreased by 21.15% to $1.4 billion in 2024, then plunged by 99.69% to $4.4 million in 2025, then jumped by 42754.55% to $1.9 billion in 2026.
- Business Quant data shows BIIB's Receivables at $1.9 billion in Q2 2026, $1.4 billion in Q1 2026, and $4.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 14.33 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 5.90 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 10.34 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 1.89 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.89 Bn |
| Mar 31, 2026 | 1.37 Bn |
| Dec 31, 2025 | 4.40 Mn |
| Sep 30, 2025 | 1.37 Bn |
| Jun 30, 2025 | 1.62 Bn |
| Mar 31, 2025 | 1.60 Bn |
| Dec 31, 2024 | 1.40 Bn |
| Sep 30, 2024 | 1.62 Bn |
| Jun 30, 2024 | 1.70 Bn |
| Mar 31, 2024 | 1.68 Bn |
| Dec 31, 2023 | 1.78 Bn |
| Sep 30, 2023 | 3.19 Bn |
| Jun 30, 2023 | 1.69 Bn |
| Mar 31, 2023 | 1.64 Bn |
| Dec 31, 2022 | 1.71 Bn |
| Sep 30, 2022 | 2.47 Bn |
| Jun 30, 2022 | 2.47 Bn |
| Mar 31, 2022 | 2.03 Bn |
| Dec 31, 2021 | 1.83 Bn |
| Sep 30, 2021 | 1.72 Bn |